{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:14Z","timestamp":1794047474433,"version":"4.8.0"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>IKZF1 deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1 loss on sensitivity to drugs used in contemporary treatment protocols has remained underexplored. Here we show in experimental models and in patients that loss of IKZF1 promotes resistance to cytarabine (AraC), a key component of both upfront and relapsed treatment protocols. We attribute this resistance, in part, to diminished import and incorporation of AraC due to reduced expression of the solute carrier hENT1. Moreover, we found elevated mRNA expression of Evi1, a known driver of therapy resistance in myeloid malignancies. Finally, a kinase directed CRISPR\/Cas9-screen identified that inhibition of either mediator kinases CDK8\/19 or casein kinase 2 can restore response to AraC. We conclude that this high-risk group of patients could benefit from alternative antimetabolites, or targeted therapies that re-sensitize leukemic cells to AraC.<\/jats:p>","DOI":"10.3324\/haematol.2023.284357","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:38:04Z","timestamp":1717688284000},"page":"3904-3917","source":"Crossref","is-referenced-by-count":6,"title":["&lt;i&gt;IKZF1&lt;\/i&gt; gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Britt M. T.","family":"Vervoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari J.T.","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorette S. van Ingen","family":"Schenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha M.","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat C.","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H.J.","family":"Van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland P.","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens T.","family":"Van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank N.","family":"Van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"69560","doi-asserted-by":"crossref","unstructured":"Reedijk AM, Coebergh JWW, de Groot-Kruseman HA. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. Leukemia. 2021; 35(4):1001-1011.","DOI":"10.1038\/s41375-020-01024-0"},{"key":"69561","doi-asserted-by":"crossref","unstructured":"Dixon SB, Chen Y, Yasui Y. Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. J Clin Oncol. 2020; 38(29):3418-3429.","DOI":"10.1200\/JCO.20.00493"},{"key":"69562","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34(22):2591-2601.","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"69563","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Su X, Zhang J. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-480.","DOI":"10.1056\/NEJMoa0808253"},{"key":"69564","doi-asserted-by":"crossref","unstructured":"Kuiper R, Waanders E, Van Der Velden V. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010; 24(7):1258-1264.","DOI":"10.1038\/leu.2010.87"},{"key":"69565","doi-asserted-by":"crossref","unstructured":"Steeghs EM, Boer JM, Hoogkamer AQ. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep. 2019; 9(1):4634.","DOI":"10.1038\/s41598-019-41078-4"},{"key":"69566","doi-asserted-by":"crossref","unstructured":"Yu J, Waanders E, van Reijmersdal SV. Upfront treatment influences the composition of genetic alterations in relapsed pediatric B-cell precursor acute lymphoblastic leukemia. Hemasphere. 2020; 4(1):e318.","DOI":"10.1097\/HS9.0000000000000318"},{"key":"69567","doi-asserted-by":"crossref","unstructured":"Marke R, Havinga J, Cloos J. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2016; 30(7):1599-1603.","DOI":"10.1038\/leu.2015.359"},{"key":"69568","doi-asserted-by":"crossref","unstructured":"Butler M, Vervoort BM, van Ingen Schenau DS. Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways. Front Oncol. 2022; 12:905665.","DOI":"10.3389\/fonc.2022.905665"},{"key":"69569","doi-asserted-by":"crossref","unstructured":"Van der Velden V, Cazzaniga G, Schrauder A. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21(4):604-611.","DOI":"10.1038\/sj.leu.2404586"},{"key":"69570","doi-asserted-by":"crossref","unstructured":"Frismantas V, Dobay MP, Rinaldi A. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017; 129(11):e26-e37.","DOI":"10.1182\/blood-2016-09-738070"},{"key":"69571","doi-asserted-by":"crossref","unstructured":"Zhu YX, Braggio E, Shi C-X. Identification of cereblonbinding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014; 124(4):536-545.","DOI":"10.1182\/blood-2014-02-557819"},{"key":"69572","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Kang J, Amatangelo M. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020; 34(4):1197-1201.","DOI":"10.1038\/s41375-019-0620-8"},{"key":"69573","doi-asserted-by":"crossref","unstructured":"Murphy B, Yin H, Maris JM. Evaluation of alternative in vivo drug screening methodology: a single mouse analysis. Cancer Res. 2016; 76(19):5798-5809.","DOI":"10.1158\/0008-5472.CAN-16-0122"},{"key":"69574","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Verwer F. Dutch ALL11 study: improved outcome for acute lymphoblastic leukemia by prolonging therapy for IKZF1 deletion and decreasing therapy for ETV6:: RUNX1, Down syndrome and prednisone poor responders. Blood. 2022; 140(Supplement 1):519-520.","DOI":"10.1182\/blood-2022-165931"},{"key":"69575","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Fiocco M. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023; 41(25):4130-4142.","DOI":"10.1200\/JCO.22.02705"},{"key":"69576","doi-asserted-by":"crossref","unstructured":"Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001; 15(6):875-890.","DOI":"10.1038\/sj.leu.2402114"},{"key":"69577","doi-asserted-by":"crossref","unstructured":"Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med. 2000; 5(6):597-604.","DOI":"10.3892\/ijmm.5.6.597"},{"key":"69578","doi-asserted-by":"crossref","unstructured":"Galmarini CM, Thomas X, Calvo F. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol. 2002; 117(4):860-868.","DOI":"10.1046\/j.1365-2141.2002.03538.x"},{"key":"69579","doi-asserted-by":"crossref","unstructured":"Churchman ML, Evans K, Richmond J. Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. JCI Insight. 2016; 1(4):e86082.","DOI":"10.1172\/jci.insight.86082"},{"key":"69580","doi-asserted-by":"crossref","unstructured":"Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene. 2007; 396(2):346-357.","DOI":"10.1016\/j.gene.2007.04.012"},{"key":"69581","doi-asserted-by":"crossref","unstructured":"Kataoka K, Sato T, Yoshimi A. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011; 208(12):2403-2416.","DOI":"10.1084\/jem.20110447"},{"key":"69582","doi-asserted-by":"crossref","unstructured":"Bindels EMJ, Havermans M, Lugthart S. EVI1 is critical for the pathogenesis of a subset of MLL-AF9\u2013rearranged AMLs. Blood. 2012; 119(24):5838-5849.","DOI":"10.1182\/blood-2011-11-393827"},{"key":"69583","doi-asserted-by":"crossref","unstructured":"Masamoto Y, Chiba A, Takezaki T. EVI1-positive AML cells show distinct features and high dependency on ETS transcription factor ERG. Blood. 2021; 138(Supplement 1):784.","DOI":"10.1182\/blood-2021-149015"},{"key":"69584","doi-asserted-by":"crossref","unstructured":"Lugthart S, Figueroa ME, Bindels E. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2011; 117(1):234-241.","DOI":"10.1182\/blood-2010-04-281337"},{"key":"69585","doi-asserted-by":"crossref","unstructured":"Li W, Xu H, Xiao T. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014; 15(12):554.","DOI":"10.1186\/s13059-014-0554-4"},{"key":"69586","doi-asserted-by":"crossref","unstructured":"Sharko AC, Lim C-U, McDermott MS. The inhibition of CDK8\/19 mediator kinases prevents the development of resistance to EGFR-targeting drugs. Cells. 2021; 10(1):144.","DOI":"10.3390\/cells10010144"},{"key":"69587","doi-asserted-by":"crossref","unstructured":"Buontempo F, McCubrey JA, Orsini E. Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia. 2018; 32(1):1-10.","DOI":"10.1038\/leu.2017.301"},{"key":"69588","doi-asserted-by":"crossref","unstructured":"Song C, Li Z, Erbe AK, Savic A, Dovat S. Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1. World J Biol Chem. 2011; 2(6):126-131.","DOI":"10.4331\/wjbc.v2.i6.126"},{"key":"69589","doi-asserted-by":"crossref","unstructured":"Song C, Gowda C, Pan X. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. 2015; 126(15):1813-1822.","DOI":"10.1182\/blood-2015-06-651505"},{"key":"69590","doi-asserted-by":"crossref","unstructured":"Bard-Chapeau EA, Gunaratne J, Kumar P. EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. Proc Natl Acad Sci U S A. 2013; 110(31):E2885-E2894.","DOI":"10.1073\/pnas.1309310110"},{"key":"69591","doi-asserted-by":"crossref","unstructured":"Rogers JH, Gupta R, Reyes JM. Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Adv. 2021; 5(19):3876-3890.","DOI":"10.1182\/bloodadvances.2020002408"},{"key":"69592","doi-asserted-by":"crossref","unstructured":"Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C) DNA, and cytotoxicity of human leukemic cells. Blood. 1984; 64(1):54-58.","DOI":"10.1182\/blood.V64.1.54.bloodjournal64154"},{"key":"69593","doi-asserted-by":"crossref","unstructured":"Wiley J, Jones S, Sawyer W, Paterson A. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest. 1982; 69(2):479-489.","DOI":"10.1172\/JCI110472"},{"key":"69594","unstructured":"Peters G, Schornagel J, Milano G. Clinical pharmacokinetics of anti-metabolites. Cancer Surv. 1993; 17:123-156."},{"key":"69595","doi-asserted-by":"crossref","unstructured":"Candelaria M, Corrales-Alfaro C, Guti\u00e9rrez-Hern\u00e1ndez O. Expression levels of human equilibrative nucleoside transporter 1 and deoxycytidine kinase enzyme as prognostic factors in patients with acute myeloid leukemia treated with cytarabine. Chemotherapy. 2016; 61(6):313-318.","DOI":"10.1159\/000445370"},{"key":"69596","doi-asserted-by":"crossref","unstructured":"Ronald W, den Boer M, Meijerink J. Differential mRNA expression of Ara-C metabolizing enzymes explain Ara-C sensitivity in MLL gene-rearrengements infant acute lymphoblastic leukemia. Blood. 2003; 101(4):1270-1276.","DOI":"10.1182\/blood-2002-05-1600"},{"key":"69597","doi-asserted-by":"crossref","unstructured":"Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018; 103(4):565-574.","DOI":"10.3324\/haematol.2017.185603"},{"key":"69598","doi-asserted-by":"crossref","unstructured":"Li Z, Li S-P, Li R-Y. Leukaemic alterations of IKZF1 prime stemness and malignancy programs in human lymphocytes. Cell Death Dis. 2018; 9(5):526.","DOI":"10.1038\/s41419-018-0600-3"},{"key":"69599","doi-asserted-by":"crossref","unstructured":"Kataoka K, Sato T, Yoshimi A. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011; 208(12):2403-2416.","DOI":"10.1084\/jem.20110447"},{"key":"69600","doi-asserted-by":"crossref","unstructured":"Hinai AA, Valk PJ. Aberrant EVI 1 expression in acute myeloid leukaemia. Br J Haematol. 2016; 172(6):870-878.","DOI":"10.1111\/bjh.13898"},{"key":"69601","doi-asserted-by":"crossref","unstructured":"Nabil R, Abdellateif MS, Gamal H. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia. Leuk Res. 2023; 126:107019.","DOI":"10.1016\/j.leukres.2023.107019"},{"key":"69602","doi-asserted-by":"crossref","unstructured":"Ferreir\u00f3s-Vidal I, Carroll T, Taylor B. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B\u2013cell differentiation. Blood. 2013; 121(10):1769-1782.","DOI":"10.1182\/blood-2012-08-450114"},{"key":"69603","doi-asserted-by":"crossref","unstructured":"de Rooij JD, Beuling E, van den Heuvel-Eibrink MM. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia. Haematologica. 2015; 100(9):1151-1159.","DOI":"10.3324\/haematol.2015.124321"},{"key":"69604","doi-asserted-by":"crossref","unstructured":"Zhang X, Huang A, Liu L. The clinical impact of IKZF1 mutation in acute myeloid leukemia. Exp Hematol Oncol. 2023; 12(1):33.","DOI":"10.1186\/s40164-023-00398-y"},{"key":"69605","doi-asserted-by":"crossref","unstructured":"Lavall\u00e9e V-P, Gendron P, Lemieux S, D\u2019Angelo G, H\u00e9bert J, Sauvageau G. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 2015; 125(1):140-143.","DOI":"10.1182\/blood-2014-07-591529"},{"key":"69606","doi-asserted-by":"crossref","unstructured":"Grygier P, Pustelny K, Nowak J. Silmitasertib (CX-4945), a clinically used CK2-kinase inhibitor with additional effects on GSK3\u03b2 and DYRK1A kinases: a structural perspective. J Med Chem. 2023; 66(6):4009-4024.","DOI":"10.1021\/acs.jmedchem.2c01887"},{"key":"69607","doi-asserted-by":"crossref","unstructured":"Borthakur GM, Donnellan WB, Solomon SR. SEL120-a first-in-class CDK8\/19 inhibitor as a novel option for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome-data from preclinical studies and introduction to a phase Ib clinical trial. Blood. 2019; 134(Supplement_1):2651.","DOI":"10.1182\/blood-2019-127835"},{"key":"69608","doi-asserted-by":"crossref","unstructured":"Cros E, Jordheim L, Dumontet C, Galmarini CM. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma. 2004; 45(6):1123-1132.","DOI":"10.1080\/1042819032000159861"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284357\/77119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284357\/77829","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11635\/77119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:38Z","timestamp":1794045998000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284357","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}